Trial Profile
A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Anaemia; Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- 26 Aug 2019 Status changed from recruiting to discontinued.
- 17 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
- 17 Aug 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2022.